These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. Cha MH; Regueiro M; Sandhu DS World J Gastroenterol; 2020 May; 26(19):2323-2332. PubMed ID: 32476796 [TBL] [Abstract][Full Text] [Related]
31. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Li P; Liu Y; Cheng Z; Yu X; Li Y Biomed Pharmacother; 2022 Oct; 154():113568. PubMed ID: 36029543 [TBL] [Abstract][Full Text] [Related]
32. A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. Karnik M; Beeraka NM; Uthaiah CA; Nataraj SM; Bettadapura ADS; Aliev G; Madhunapantula SV Mol Neurobiol; 2021 Sep; 58(9):4535-4563. PubMed ID: 34089508 [TBL] [Abstract][Full Text] [Related]
33. COVID-19 and the liver: overview. Amin M Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):309-311. PubMed ID: 32558697 [TBL] [Abstract][Full Text] [Related]
34. Findings of Hepatic Severe Acute Respiratory Syndrome Coronavirus-2 Infection. Fiel MI; El Jamal SM; Paniz-Mondolfi A; Gordon RE; Reidy J; Bandovic J; Advani R; Kilaru S; Pourmand K; Ward S; Thung SN; Schiano T Cell Mol Gastroenterol Hepatol; 2021; 11(3):763-770. PubMed ID: 32992052 [TBL] [Abstract][Full Text] [Related]
35. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
36. Liver injury during highly pathogenic human coronavirus infections. Xu L; Liu J; Lu M; Yang D; Zheng X Liver Int; 2020 May; 40(5):998-1004. PubMed ID: 32170806 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of severe acute respiratory syndrome coronavirus-2 induced liver damage and alteration of some liver biomarkers: A review. Seyoum F Medicine (Baltimore); 2023 May; 102(19):e33517. PubMed ID: 37171303 [TBL] [Abstract][Full Text] [Related]
38. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Zhong P; Xu J; Yang D; Shen Y; Wang L; Feng Y; Du C; Song Y; Wu C; Hu X; Sun Y Signal Transduct Target Ther; 2020 Nov; 5(1):256. PubMed ID: 33139693 [TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
40. Pneumocytes are distinguished by highly elevated expression of the ER stress biomarker GRP78, a co-receptor for SARS-CoV-2, in COVID-19 autopsies. Puzyrenko A; Jacobs ER; Sun Y; Felix JC; Sheinin Y; Ge L; Lai S; Dai Q; Gantner BN; Nanchal R; North PE; Simpson PM; Rui H; Benjamin IJ Cell Stress Chaperones; 2021 Sep; 26(5):859-868. PubMed ID: 34382151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]